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Left  atrial  size  is  an  independent  predictor  of  overall
survival  in  patients  with  primary  systemic
amyloidosis
Le  diamètre  de  l’oreillette  gauche  est  un  prédicteur  indépendant  de  mortalité
chez  les  patients  ayant  une  amylose  primitive  à  chaînes  légères
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Summary
Background.  —  Primary  systemic  amyloidosis  is  a  severe  plasma  cell  disorder  characterized  by
the extracellular  deposition  of  amyloid  ﬁbrils  in  different  organs.  Echocardiography  is  usually
performed to  assess  cardiac  involvement.  We  hypothesized  that  in  patients  with  systemic  amy-
loidosis, simple  echocardiographic  measurement  of  the  left  atrial  (LA)  diameter  indexed  to  theSurvival body surface  area  might  provide  an  important  risk  marker  for  this  disease.
Methods.  —  Between  1997  and  2011,  134  patients  were  diagnosed  with  primary  systemic  amy-
loidosis and  had  echocardiography  within  28  days;  we  collected  their  baseline  characteristics
and biological  and  echocardiographic  data  retrospectively.  LA  enlargement  was  deﬁned  as
recommended  as  M-mode  LA  diameter  greater  or  equal  to  23  mm/m2.
Abbreviations: IVST, InterVentricular Septal Thickness; LA, Left Atrium/Atrial; LADi, Left Atrial Diameter Indexed to body surface
area; LV, Left Ventricular; LVEF, Left Ventricular Ejection Fraction; TTE, TransThoracic Echocardiography.
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Results.  —  One  hundred  and  eleven  patients  (83%)  had  echocardiographic  LA  dimension  data
available (mean  age  63  ±  11  years;  61%  men;  31%  previously  diagnosed  with  systemic  hyper-
tension). Mean  left  ventricular  ejection  fraction  (LVEF)  and  interventricular  septum  thickness
(IVST) were  62  ±  12%  and  14  ±  4  mm,  respectively.  Mean  follow-up  was  2.8  ±  2.9  years  (maximum
12 years).  Patients  with  LA  enlargement  had  a  slightly  lower  LVEF  (P  =  0.08)  and  a  signiﬁcantly
greater IVST  (P  <  0.0001).  Overall,  5-year  survival  was  57  ±  5%.  However,  1-year  and  5-year
survival rates  were  markedly  reduced  in  patients  with  LA  enlargement  versus  those  without  LA
enlargement  (61  ±  7%  and  39  ±  8%  vs  83  ±  5%  and  72  ±  7%,  respectively;  P  =  0.0007).  On  multivari-
able analysis,  after  adjusting  for  age,  sex,  LVEF,  IVST,  presence  of  hypertension  and  creatinine
concentration,  LA  enlargement  remained  an  independent  predictor  of  overall  mortality  at  5
years (hazard  ratio  2.47;  95%  conﬁdence  interval  1.11—5.90;  P  =  0.02).
Conclusion.  —  LA  enlargement,  a  surrogate  marker  of  diastolic  dysfunction,  is  an  independent
predictor  of  long-term  mortality  and  may  therefore  help  to  enhance  risk  stratiﬁcation  and
management  of  patients  presenting  with  amyloidosis.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’amylose  systémique  à  chaînes  légères  (AL)  est  une  maladie  grave  caractérisée  par
des dépôts  de  ﬁbrilles  amyloïdes  dans  différents  organes.  L’échocardiographie  transthoracique
est l’examen  le  plus  couramment  réalisé  pour  évaluer  l’atteinte  cardiaque.  Nous  avons  émis
l’hypothèse  que  chez  des  patients  présentant  cette  maladie,  une  simple  mesure  du  diamètre
de l’oreillette  gauche  par  échocardiographie  peut  être  un  important  marqueur  pronostique.
Méthodes.  —  Nous  avons  comparé  les  données  au  diagnostic  de  134  patients  pris  en  charge  pour
une amylose  AL  systémique  entre  1997  et  2011  dans  notre  centre.  Cent  onze  patients  (83  %)
parmi eux  avaient  une  échographie  cardiaque  dans  les  28  jours  suivant  le  diagnostic.  La  dilata-
tion de  l’oreillette  gauche  a  été  déﬁnie  tel  que  recommandé,  par  un  diamètre  supérieur  ou  égal
à 23  mm/m2.  Les  données  démographiques,  biologiques  et  échographiques  ont  été  collectées
de fac¸on  rétrospective.
Résultats.  —  Dans  la  population  d’étude  de  111  patients,  l’âge  moyen  est  63  ±  11  ans  ;  61  %  sont
de sexe  masculin  et  31  %  ont  des  antécédents  d’hypertension  artérielle.  Le  temps  de  suivi  moyen
était de  2,8  ans  (max  12  ans).  Les  patients  avec  oreillette  gauche  dilatée  supérieure  ou  égale  à
23 mm/m2 avaient  une  fraction  d’éjection  plus  basse  et  un  septum  interventriculaire  signiﬁca-
tivement  plus  épaissi.  La  survie  globale  à  cinq  ans  était  de  57  ±  5  %.  Toutefois,  ce  taux  de  survie
à un  et  cinq  ans  était  signiﬁcativement  diminué  chez  les  patients  avec  une  oreillette  dilatée  :
61 ±  7  %  et  39  ±  8  %  contre  83  ±  5  %  et  72  ±  7  %  respectivement  chez  ceux  dont  l’oreillette  n’est
pas dilatée  (p  =  0,0007).  En  analyse  multivariée,  après  ajustement  pour  l’âge,  le  sexe,  la  fraction
d’éjection  ventriculaire  gauche,  la  présence  d’hypertension,  l’épaisseur  du  septum  et  la  créat-
inémie, la  dilatation  de  l’oreillette  gauche  reste  un  facteur  indépendant  prédictif  de  mortalité
globale à  cinq  ans  (HR  2,47  ;  95  %  CI  1,11—5,90  ;  p  =  0,02).
Conclusion.  —  La  dilatation  de  l’oreillette  gauche,  est  un  marqueur  indépendant  de  mortalité
à long  terme,  qui  peut  contribuer  à  améliorer  la  stratiﬁcation  du  risque  et  la  prise  en  charge
des patients  présentant  une  amylose  AL  primitive.
© 2011  Elsevier  Masson  SAS.  Tous  droits  réservés.
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gackground
rimary  systemic  amyloidosis  is  a  severe  plasma  cell  dis-
rder  characterized  by  the  deposition  of  amyloid  ﬁbrils  in
ifferent  organs.  This  process  damages  the  involved  organs
nd  impairs  their  function.  Myocardial  involvement  is  not
nusual  [1]  in  patients  with  primary  systemic  amyloidosis
nd  results  in  progressive  heart  failure;  thus,  it  has  a  major
mpact  on  prognosis.  Without  speciﬁc  treatment,  median
urvival  is  less  than  6  months  for  symptomatic  patients  [2].
TE  is  the  most  common  test  performed  to  diagnose  car-
iac  involvement.  When  cardiac  involvement  is  suspected,
TE  may  show  typically:  hypertrophied  LV  walls,  left  atrial
nlargement,  LV  diastolic  dysfunction  and,  at  a  later  stage,
g
L
aevere  restrictive  cardiac  pattern.  The  LA  is  an  important
eature  of  diastolic  dysfunction  [3]  and  the  degree  of  LA
nlargement  is  directly  related  to  the  impairment  of  LV
ysfunction  in  different  cardiac  diseases  where  diastolic  dys-
unction  is  predominant.
In  the  last  few  years,  it  has  been  shown  that  LA  size,
s  measured  by  TTE,  confers  independent  prognostic  infor-
ation  regarding  cardiovascular  events  and  mortality  after
onsideration  of  various  known  clinical  and  echocardio-
raphic  predictors  [3—6].The LA  diameter,  as  measured  by  TTE,  is  a  valid  surro-
ate  of  LA  size  although  less  precise  than  the  calculated
A  volume  [6,7]. It  is  more  easily  obtainable,  reproducible
nd  less  time  consuming  to  measure  than  LA  volume;  in
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aLeft  atrial  size  and  survival  in  primary  systemic  amyloidosis  
fact,  measurement  of  the  LA  diameter  has,  for  a  long  time,
been  a  part  of  the  standard  echocardiographic  evaluation
and  in  previous  studies  it  has  been  correlated  with  outcome
and  prognosis  in  other  heart  diseases  [4,8]. Accordingly,  we
sought  to  determine  whether  this  very  simple  measurement
might  provide  important  prognostic  information  in  patients
with  primary  systemic  amyloidosis.
The  purpose  of  this  study  was  to  determine  the  prog-
nostic  value  of  LA  size  in  patients  with  primary  systemic
amyloidosis.
Methods
Patient population
The  study  included  134  patients  with  conﬁrmed  primary
systemic  amyloidosis  who  were  admitted  to  the  CHU  Limo-
ges  haematology  department  between  June  1997  and  April
2011.  The  diagnosis  was  conﬁrmed  by  an  organ  biopsy  that
demonstrated  typical  Congo  red  birefringence  under  polar-
ized  light,  further  conﬁrmed  by  the  presence  of  monoclonal
proteins  in  the  serum  and/or  a  monoclonal  population  of
plasma  cells  in  the  bone  marrow  [9].
Patients  with  localized  amyloidosis  or  a  history  of  familial
or  senile  amyloidosis  were  excluded  from  our  study.  Affected
organs  were  determined  based  on  standard  criteria  for  the
evaluation  of  systemic  amyloidosis  [10].
In  our  study  population,  67  patients  (60%)  with  pri-
mary  systemic  amyloidosis  were  considered  to  have  cardiac
involvement  on  the  basis  of  clinical  history,  typical
electrocardiographic  features  of  cardiac  amyloidosis  and
echocardiographic  signs,  which  were:  LV  wall  thickness
greater  than  12  mm  (in  the  absence  of  other  causes  of  LV
hypertrophy),  diastolic  dysfunction,  dilated  LA,  pericardial
effusion  and/or  thickened  free  right  ventricular  wall.
Patients  were  mainly  treated  with  conventional
chemotherapy,  usually  the  M-Dex  regimen  (melphalan
and  dexamethasone),  or  with  new  drugs  (thalidomide,
bortezomib  and  lenalidomide)  for  non-responders  after
2005.
Data collection
We  performed  a  retrospective  collection  of  demographic,
clinical,  biological  and  TTE  data  using  patients’  charts.
Survival  data  were  obtained  from  death  certiﬁcates,  fam-
ily  physician  questionnaires  or  hospital  records.  To  avoid
misclassiﬁcation  of  the  cause  of  death,  all-cause  mortal-
ity  was  selected  as  the  endpoint.  Ninety-eight  percent  of
patients  had  their  follow-up  completed  by  April  2011.  LA
diameter  data  were  available  for  111/134  (83%)  patients
included  in  the  study.  Doppler-echocardiographic  measure-
ments  included  assessment  of  LV  systolic  and  diastolic
function,  LV  end-diastolic  diameter  and  LV  end-systolic
diameter,  and  LVEF  was  calculated  using  the  Teicholz  and/or
Simpson  method  according  to  American  Society  of  Echocar-
diography  and  European  Association  of  echocardiography
recommendations  [11]. LA  anteroposterior  diameter  was
measured  by  M-mode  TTE  in  parasternal  long-axis  view  and
was  indexed  to  body  surface  area  (LADi).  The  cutoff  of
greater  or  equal  to  23  mm/m2 for  LADi  was  used  to  deﬁne
I
(
t613
A  enlargement  as  suggested  in  the  recommendations  of  the
uropean  Association  of  echocardiography  [11].
tatistical analysis
atients  were  divided  into  two  groups  according  to  LA  size.
atients  with  LADi  greater  or  equal  to  23  mm/m2 were  con-
idered  to  have  LA  enlargement,  whereas  those  with  LADi
ess  than  23  mm/m2 were  considered  to  have  a  normal-sized
A.  Continuous  data  were  expressed  as  mean  ±  standard
eviation  and  were  compared  by  Student’s  t  test,  using
ommercially  available  software  (JMP  7-1).  Categorical  data
ere  given  as  percentages  and  were  compared  using  the  Chi2
est.  A  P  value  less  than  0.05  was  considered  as  statistically
igniﬁcant.
The  primary  endpoint  was  overall  survival  calculated
rom  the  time  of  ﬁrst  diagnosis  of  amyloidosis  until  the  date
f  last  available  follow-up.  The  cumulative  probability  of  an
vent  for  the  survival  endpoint  was  estimated  by  the  Kaplan-
eier  method  and  results  are  presented  at  1  and  5  years.
og-rank  tests  were  used  to  test  for  signiﬁcance  in  survival
etween  the  two  groups.  We  ﬁrst  performed  a  univariate  Cox
roportional  hazard  analysis  to  test  the  association  between
urvival  and  the  most  clinically  relevant  variables,  as  well
s  some  echocardiographic  variables  that  were  available  in
ur  dataset  and  are  known  to  affect  survival  rate  in  this  pop-
lation.  We  then  performed  a  multivariable  analysis  that
ncluded  age,  sex,  presence  of  hypertension  and  the  vari-
bles  that  were  signiﬁcant  in  the  univariate  analysis.  Results
ere  reported  as  hazard  ratios  with  the  corresponding  conﬁ-
ence  interval  of  probability  values.
esults
he  study  population  consisted  of  111/134  patients  who
ere  referred  to  the  CHU  Limoges  haematology  department
ith  echocardiographic  data  available  at  baseline.  Fifty-
hree  (54%)  of  the  111  patients  had  LA  enlargement  (LADi
 23  mm/m2).
aseline characteristics of the total population
mong  the  111  patients,  61%  were  men,  the  mean  age  was
3  ±  11  years,  31%  had  a  history  of  hypertension  and  10%
ad  atrial  ﬁbrillation  or  a  documented  history  of  paroxys-
al  atrial  ﬁbrillation  at  baseline.  Sixty-one  percent  of  the
atients  had  renal  involvement  based  on  standard  criteria
or  the  evaluation  of  affected  organs  [10]. Similarly,  cardiac
nvolvement,  as  deﬁned  above,  was  found  in  60%  of  patients.
ean  LVEF  was  62  ±  12%;  mean  IVST  was  14  ±  4  mm.  Other
aseline  characteristics  are  shown  in  Table  1.  It  should  be
oted  that  E/E’  ratio  obtained  at  the  lateral  side  of  the
itral  annulus  was  available  only  in  65%  of  the  study  popu-
ation  and  the  mean  E/E’lat  was  15  ±  7.
omparison of patients with and without left
trium enlargementn  our  series,  patients  with  LA  enlargement  were  older
66  ±  11  vs  59  ±  11  years;  P  =  0.0002)  compared  with
hose  without  LA  enlargement,  but  the  groups  were  not
614  D.  Mohty  et  al.
Table  1  Clinical,  biological  and  echocardiographic  data  of  patients  with  LA  enlargement  compared  with  those  without
LA  enlargement.
Clinical  data  All  (n  =  111)  Without  LA  enlargement
(n  =  58)
With  LA  enlargement
(n  =  53)
Pa
Age  (years)  63  ±  11  59  ±  11  66  ±  11  0.0002
Men  61  60  60  0.99
Body  surface  area  (m2)  1.79  ±  0.19  1.79  ±  0.2  1.79  ±  0.18  0.94
Organ  involvement  >  2 76 69 83 0.08
Renal  involvement 61 59 62 0.69
Cardiac  involvement 60 47 75 0.001
24-hour  proteinuria  (g/24  hours)  3.8  ±  5.2  4.8  ±  6  2.8  ±  3.6  0.06
  FLC  (mg/L)  566  ±  972  589  ±  1210  563  ±  655  0.89
Creatinine  level  (mol/L)  139  ±  152  111  ±  113  167  ±  182  0.08
Hypertension  31  23  38  0.1
CAD  4  2  6  0.3
Atrial  ﬁbrillation  10  4  16  0.03
Microvoltage  30  26  34  0.4
LVEDD  (mm)  43  ±  6  44  ±  7  43  ±  6  0.2
LVESD  (mm)  28  ±  5  28  ±  5  28  ±  5  0.8
IVST  (mm)  14  ±  4  13  ±  3  15  ±  4  <  0.0001
IVST  >  12  mm  55  40  74  <  0.0004
LVEF  (%)  62  ±  12  64  ±  11  60  ±  13  0.08
LVEF  <  50%  17  13  24  0.01
E/A  1.98  ±  4.2  1.19  ±  0.8  2.79  ±  5.6  0.08
DT  (ms)  214  ±  89  228  ±  84  201  ±  94  0.2
E/E’lat  15  ±  7  12  ±  7  17  ±  8  0.02
E/E’lat  >  13  51  38  58  0.05
LAD  (mm)  40  ±  8  35  ±  5  45  ±  6  <  0.0001
LADi  (mm/m2)  22.6  ±  4  20  ±  2  26  ±  3  <  0.0001
Death  43  33  55  0.01
Data are mean ± standard deviation or % of patients. CAD: coronary artery disease; DT: deceleration time;  FLC: delta free light
chain; IVST: interventricular septal thickness; LA: left atrium; LAD: left atrial diameter; LADi: left atrial diameter indexed to body
surface area; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic
diameter.
a Comparison of patients without LA enlargement (LADi < 23 mm/m2) versus those with LA enlargement (LADi ≥ 23 mm/m2).
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tigniﬁcantly  different  in  terms  of  sex,  presence  of  hyper-
ension,  monoclonal  free  light  chain  involved  and  renal
nvolvement  (all  P  >  0.05;  Table  1).  However,  patients  with
A  enlargement  had  signiﬁcantly  more  cardiac  involve-
ent  (75%  vs  47%;  P  =  0.001)  and  more  atrial  ﬁbrillation
16%  vs  4%;  P  =  0.03).  Mean  LVEF  was  also  slightly  lower
60  ±  13%  vs  64  ±  11%;  P  =  0.08)  in  the  group  with  LA
nlargement  compared  with  the  group  without  LA  enlarge-
ent.
ong-term outcome of patients with primary
ystemic amyloidosis according to left atrium
ize
ollow-up  data  were  available  for  98%  of  patients.  The  mean
ollow-up  time  was  2.8  ±  2.9  years  (maximum  12  years).
verall,  there  were  49  deaths.  The  overall  1-year  and  5-
ear  survival  rates  were  72  ±  4%  and  57  ±  5%,  respectively.
he  long-term  survival  rates  at  1  and  5  years,  respectively,
or  patients  with  LA  enlargement  (61  ±  7%  and  39  ±  8%)  were
igniﬁcantly  lower  than  in  patients  without  LA  enlargement
83  ±  5%  and  72  ±  7%;  P  =  0.0007;  Fig.  1A).
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inivariate and multivariable predictors of
ortality in patients with primary systemic
myloidosis
s  shown  in  Table  2,  on  univariate  analysis,  the  predictors  of
urvival  were:  age,  IVST  greater  than  12  mm,  decreased  LVEF
ess  than  50%,  plasma  creatinine  concentration  and  LADi  at
aseline  diagnostic  echocardiogram.  Also,  the  E/E’  ratio  (at
he  lateral  side  of  mitral  annulus)  was  available  for  only  74
atients  and  did  not  reach  statistical  signiﬁcance  on  uni-
ariate  analysis  (P  =  0.1).  However,  the  presence  of  atrial
brillation,  a  history  of  hypertension,  coronary  artery  dis-
ase,  renal  involvement,  the  plasma  free  light  chains  and
4-hour  proteinuria  did  not  appear  as  univariate  predictors
f  survival.
On  multivariable  analysis  (Table  3),  after  adjusting  for
ge  and  sex,  the  presence  of  hypertension  and  the  variables
hat  were  signiﬁcant  predictors  of  survival  in  the  univari-
te  analysis  (creatinine  concentration,  IVST  and  LVEF),  LADi
reater  or  equal  to  23  mm/m2 remained  an  independent  pre-
ictor  of  late  mortality  (hazard  ratio  2.47;  95%  conﬁdence
nterval  1.11—5.90;  P  =  0.02).
Left  atrial  size  and  survival  in  primary  systemic  amyloidosis  
Table  2  Univariate  predictors  of  late  overall  survival.
Variables  Hazard  ratio  [95%  CI]  P
Agea (years)  1.03  [1.00—1.06] 0.03
Sex  (female)  1.25  [0.93—1.72] 0.14
No.  of  organs
involved  >  2
1.27  [0.90—1.89] 0.2
Renal
involvement
1.08  [0.79—1.49] 0.63
Alkaline
phosphatasea
(UI/L)
1.00  [0.99—1.00] 0.25
Creatininea
(mol/L)
1.0023  [1.0008—1.0034] 0.02
  Free  light
chainsa (mg/L)
1.00  [0.99—1.00] 0.1
Proteinuriaa
(g/24  hours)
0.99  [0.91—1.05] 0.8
Atrial  ﬁbrillation  1.03  [0.62—2.09] 0.91
Hypertension  1.12  [0.71—1.41] 0.94
CAD  1.08  [0.50—4.57] 0.87
IVST  >  12  mm  1.49  [1.09—2.04] 0.01
LVEF  <  50%  1.48  [1.01—2.12] 0.04
E/E’lat  >  13  1.39  [0.96—2.08] 0.1
LA  enlargement
(LADi  ≥  23  mm/
m2)
2.77 [1.52—5.25] 0.0008
CAD: coronary artery disease; CI: conﬁdence interval; IVST:
interventricular septal thickness; LA: left atrium; LADi: left
atrial diameter indexed to body surface area; LVEF: left
ventricular ejection fraction.
a For variables expressed in continuous format, the hazard ratio
(HR) represents the increase in mortality risk per 1-unit increase
in the variable; for categorical variables, the HR represents the
risk of mortality in the presence of the variables.
Table  3  Multivariable  predictors  of  late  overall
survival.
Variables  Multivariable  analysis
Hazard  ratio  [95%  CI]  P
Agea (years)  1.04  [1.01—1.08] 0.01
Sex  (female)  1.28  [0.93—1.78] 0.1
Creatininea
(mol/L)
1.0023  [1.0008—1.0034] 0.04
Hypertension  —  NS
Atrial  ﬁbrillation  —  NS
IVST  >  12  mm  1.31  [0.90—1.96] 0.1
LVEF  <  50%  1.58  [1.09—2.27] 0.01
LA  enlargement
(LADi  ≥  23  mm/m2)
2.47  [1.11—5.90] 0.02
CI: conﬁdence interval; IVST: interventricular septal thickness;
LA: left atrium; LADi: left atrial diameter indexed to body
surface area; LVEF: left ventricular ejection fraction.
a For variables expressed in continuous format, the hazard ratio
(HR) represents the increase in mortality risk per 1-unit increase
in the variable; for categorical variables, the HR represents the
risk of mortality in the presence of the variables.
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rognostic value of left  atrium enlargement in
he subgroup of patients with presumed
myloid heart involvement
n  the  subset  of  patients  (n  =  67;  60%)  with  apparent  car-
iac  involvement  as  previously  deﬁned,  LA  enlargement
emained  a  powerful  predictor  of  survival  (Fig.  1B),  with
aplan-Meier  survival  rates  of  78  ±  8%  and  62  ±  10%  at  1  and
 years,  respectively,  in  the  group  without  LA  enlargement
ersus  51  ±  8%  and  34  ±  9%  in  the  group  with  LA  enlargement
igure 1. A. Kaplan-Meier 1-year and 5-year survival curves for
atients with systemic primary amyloidosis. B. Kaplan-Meier 1-year
nd 5-year survival curves in the subgroup of patients with systemic
rimary amyloidosis and apparent cardiac involvement. Dotted line,
nlarged left atrial diameter indexed to body surface area (LADi);
ontinuous line, normal LADi.
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P  =  0.01);  This  association  again  remained  statistically  sig-
iﬁcant  on  multivariable  analysis,  after  adjusting  for  age,
ex  and  LVEF  (hazard  ratio  2.3;  95%  conﬁdence  interval
.02—5.50;  P  =  0.04).
iscussion
he  main  ﬁnding  of  the  present  study  is  that  LA  enlargement
s  a  frequent  ﬁnding  and  is  a  strong  and  independent  pre-
ictor  of  mid-term  and  long-term  survival  in  patients  with
rimary  systemic  amyloidosis.
Using  a  simple  parameter  (anteroposterior  LADi)  mea-
ured  by  M-mode  TTE,  we  were  indeed  able  to  show  that
A  enlargement  was  an  independent  predictor  of  total  long-
erm  survival,  with  an  almost  2.5-fold  increase  in  the  risk
f  overall  mortality,  even  after  adjusting  for  other  impor-
ant  and  independent  predictors  of  mortality  in  this  high-risk
opulation.  LADi  was  also  a  predictor  of  survival  in  the  sub-
roup  of  patients  with  apparent  cardiac  involvement.
To  our  knowledge,  this  is  the  ﬁrst  study  of  more  than
00  patients  with  systemic  amyloidosis  who  were  seen  at  a
ingle  centre  and  had  a  fairly  long-term  follow-up,  that  has
hown  that  a  simple  and  easy  echocardiographic  variable
hat  can  be  performed  very  quickly  in  routine  practice  has
n  important  prognostic  implication  in  long-term  follow-up.
linical signiﬁcance of left atrium enlargement
iastolic  dysfunction  can  develop  early  in  the  course  of
ystemic  amyloidosis,  sometimes  before  LV  walls  become
everely  hypertrophied.  Diastolic  dysfunction  results  in  ele-
ated  LV  ﬁlling  pressures  that  are  transmitted  back  to  the
A.  The  thin  atrial  wall  may  be  affected  by  increased  load
12]  and  the  elevated  LA  pressures  required  to  maintain
dequate  diastolic  ﬁlling  result  in  LA  wall  tension  and  LA
nlargement.  LA  size  is  closely  linked  to  LV  diastolic  dysfunc-
ion  and  may  be  a  marker  of  severity  and  chronicity  [13].
LA  enlargement  is  regarded  as  an  important  prognos-
ic  factor  in  various  heart  diseases.  In  fact,  some  previous
tudies  using  LA  dimensions  measured  by  M-mode  echocar-
iography  to  assess  LA  remodelling  or,  more  recently,
sing  LA  volume  obtained  by  the  Simpson  two-dimensional
ethod,  have  demonstrated  that  increased  LA  size  is  related
o  increased  morbidity,  such  as  atrial  ﬁbrillation  [14], future
troke  and  mortality  [15]  in  patients  with  different  cardio-
ascular  diseases  [3,8,16—19]. Classical  echocardiographic
escriptions  of  cardiac  involvement  in  systemic  primary
myloidosis  include—in  addition  to  small  LV  size—increased
iventricular  free  wall  and  septal  atrial  thickening  com-
ined  with  preserved  or  slightly  depressed  LVEF  and  enlarged
tria.  However,  to  our  knowledge,  no  study  has  shown  the
rognostic  value  of  enlarged  atria,  whether  assessed  by
iameter,  surface  or  volume,  in  this  particular  disease.  Sur-
risingly,  in  a  study  by  Bellavia  et  al.  [20]  that  tested  the
mpact  of  multiple  clinical,  biological  and  echocardiographic
ariables  on  overall  survival  in  a  large,  primary  systemic
myloidosis  cohort,  LA  volume  did  not  come  out  as  a  uni-
ariate  or  independent  predictor  of  survival,  suggesting,
erhaps,  different  patient  recruitment  or  interaction  with
ther  related  diastolic  dysfunction  variables.  Although  our
tudy,  because  of  its  retrospective  design,  did  not  use  the
a
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most  modern’  method  of  assessing  LA  size  (i.e.  the  volu-
etric  method),  we  were  able  to  show  that  anteroposterior
ADi  is  a  powerful  predictor  of  long-term  overall  survival,
ndependent  of  other  predictors  of  mortality,  such  as  LVEF,
V  wall  thickness,  age  and  sex.  Another  study,  published  by
odesto  et  al.  in  2005,  showed  that  LA  function  assessed  by
train  imaging  was  decreased  in  patients  with  primary  amy-
oidosis  compared  with  controls  [21], suggesting  that  true
A  myopathy  is  present  in  patients  with  primary  systemic
myloidosis  with  presumed  cardiac  involvement.  However,
he  LA  Doppler  strain  imaging  technique  is  a  difﬁcult  and
ime-consuming  method  that  requires  ofﬂine  measurements
nd  a  long  learning  curve,  with  some  interobserver  and
ntraobserver  reproducibility  issues.  Finally,  another  paper,
ublished  by  Fitzgerald  et  al.  in  2011  [22], showed  that  LA
ilatation  was  more  pronounced  in  patients  with  cardiac
myloidosis  when  compared  with  those  with  hypertensive
isease  for  the  same  degree  of  LV  hypertrophy,  suggesting
gain  the  direct  toxicity  of  light  chains  on  the  LA  and  the
resence  of  true  atrial  myopathy  in  this  disease.  This  article
y  Fitzgerald  et  al.  is  in  accordance  with  our  present  results,
uggesting  that  LA  enlargement  may  be  ‘another  differen-
iator’  or  marker  of  cardiac  amyloidosis  in  presence  of  LV
ypertrophy.
LA  size  that  is  a  marker  of  diastolic  dysfunction  and
levated  LV  ﬁlling  pressure  may,  therefore,  be  a  use-
ul  marker  for  risk  stratiﬁcation  at  baseline  and  clinical
ecision-making,  in  patients  with  primary  systemic  amyloi-
osis.  In  fact,  prognosis  of  primary  amyloidosis  has  improved
ecently,  with  better  survival  at  5  years  compared  with  a
ortality  rate  that  was  very  high  in  this  population  a  few
ears  ago.  This  improvement  is  mainly  due  to  the  ‘modern’
reatment  recently  proposed—particularly  the  use  of  new
rugs  such  as  thalidomide,  bortezomib  and  lenalidomide,
n  addition  to  conventional  chemotherapy  (dexametha-
one  and  melphalan).  Consequently,  LA  enlargement—a
arker  of  advanced  diastolic  dysfunction  and  high  LV  ﬁll-
ng  pressure—if  detected  earlier,  may  provide  an  incentive
n  the  near  future  to  treat  these  patients  ‘maybe’  more
ggressively,  using  these  new,  more  efﬁcient  drugs  as  ﬁrst-
ine  treatment.  In  addition  to  this  potential  clinical  impact
f  detecting  LA  enlargement,  and  although  diuretic  treat-
ent  is  mainly  based  on  clinical  signs,  LA  enlargement  may
elp  to  differentiate  those  with  high  LV  ﬁlling  pressure  who
eed  higher  doses  of  diuretics  from  those  with  less  severe
iastolic  dysfunction.
linical implications
ur  study  may  have  important  clinical  implications  because
t  contributes  to  enhancing  the  risk  stratiﬁcation  of
atients  with  systemic  amyloidosis,  independent  of  the
ther  predictors  of  mortality.  We  chose  a  very  simple
ariable  that  is  easily  measured  by  all  echocardiographs
nd  echocardiographers  and  is  not  time  consuming  in
outine  practice.  This  variable  (i.e.  the  anteroposterior
-mode  LADi),  although  less  precise  compared  with  LA
olume,  was  able  to  predict  independently  overall  1-year
nd  5-year  survival  in  a population  known  to  have  fre-
uent  LV  diastolic  function  et  elevated  LV  ﬁlling  pressures.
uick,  non-invasive  measurement  of  LA  size  may  there-
ore  be  a  useful  marker  for  risk  stratiﬁcation  and  clinical
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decision-making  in  this  particular  population  (such  as  the  use
of  more  aggressive  drugs  as  ﬁrst-line  treatment  or  the  intro-
duction  of  diuretics,  for  instance,  before  peripheral  signs  of
cardiac  congestion  appear).
Study limitations
Our  study  was  retrospective  in  design:  demographic,  clini-
cal,  biological  and  echocardiographic  data  were  collected
retrospectively  reviewing  patients’  medical  charts.  Out-
come  data  were  also  obtained  retrospectively  from  patients’
charts,  death  certiﬁcates  or  family  doctor  questionnaires.
Therefore,  the  exact  cause  of  death  was  not  always  avail-
able.  That  is  why  the  main  endpoint  in  our  study  was  overall
death  and  not  cardiovascular  death.
Some  objections  may  be  raised  against  the  use  of  LA
dimension  obtained  by  M-mode  TTE  as  a  measure  of  LA
enlargement.  In  fact,  recent  studies  have  shown  that  LA  size
obtained  by  two-dimensional  echocardiography  using  volu-
metric  assessment  is  superior  to  LAD  or  LA  area  [6].  However,
LA  volumetric  data  were  not  widely  available  in  TTE  reports
at  the  time  of  inclusion  (from  1997  onwards),  whereas  LAD
by  M-mode  TTE  constituted  routine  echocardiographic  data
and  was  available  for  almost  all  patients  included.  In  addi-
tion,  although  previous  studies  have  shown  the  superiority  of
LA  volume  for  predicting  outcomes,  many  echocardiography
reports  in  our  institution  still  do  not  include  the  LA  volume
indexed  because  of  the  longer  time  that  this  measurement
requires.  Pro-brain  natriuretic  peptide  and  troponin  Ic  or
T  have  been  shown  to  be  powerful  predictors  of  outcome
in  primary  systemic  amyloidosis  patients  and  have  become
part  of  the  routine  biological  tests  performed  for  these
patients,  especially  when  cardiac  involvement  is  suspected.
In  our  study,  because  of  its  retrospective  design  (from  1997
onwards),  only  65  of  the  134  patients  had  those  measure-
ments  performed;  in  fact  N-terminal  pro-brain  natriuretic
peptide  and  troponin  have  been  measured  in  our  institution
systematically  only  since  2007  in  the  context  of  this  disease,
so  we  could  not  test  the  prognostic  value  of  these  biological
variables  in  our  population.  Other  variables,  such  as  pulsed
Doppler  tissue  imaging  (E/E’  measured  at  the  sepal  or  lateral
side  of  the  mitral  annulus),  have  been  shown  to  be  markers
of  diastolic  function  and  to  predict  high  LV  ﬁlling  pressure
[23]  in  various  diseases.  This  modern  variable  was  not  mea-
sured  in  the  late  1990s  and  was  therefore  available  in  our
study  group  only  for  65%  of  the  patients  included.  Because
of  the  limited  number  of  patients  with  this  variable,  we  did
not  test  it  in  the  multivariable  analysis.
The  presence  of  hypertension  in  31%  of  the  patients
included  in  our  study  may  be  a  confounding  factor  because
it  leads  chronically  to  LV  hypertrophy,  which  causes  diastolic
dysfunction  and  LA  dilatation;  However,  when  tested  in  the
univariate  and  multivariable  analyses,  as  shown  in  Table  2,
the  presence  of  hypertension  did  not  emerge  as  a  predictor
of  survival  in  our  population.
ConclusionIn  patients  with  systemic  primary  amyloidosis,  LA  enlarge-
ment  (a  surrogate  marker  of  diastolic  dysfunction,  elevated
LV  ﬁlling  pressure  and  chronicity),  appeared  to  be  a  strong
[617
ndependent  predictor  of  long-term  mortality.  Therefore,
A  enlargement  may  help  to  enhance  risk  stratiﬁcation  and
anagement  of  patients  presenting  with  this  disease.
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